India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#276- Valuation
- ₹20,400 Cr
2023 #316 2022 #331 2021 #304
Market Cap
₹16,626 Cr
ERIS · NSE
Share Price
₹1,175.40
-1.92% today
Revenue
₹3,129 Cr
FY 2025-26 · +8.2% YoY
EBITDA
₹1,103 Cr
Margin 35.2%
Net Profit
₹632 Cr
FY 2025-26 · +81.0% YoY
P/E (TTM)
20.5x
P/B 3.7x
ROE
19.2%
ROCE 14.1%
Debt / Equity
0.72
Interest cover 23.4x
About Eris Lifesciences Limited
Data last updated:
Eris Lifesciences Limited is a public limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 January 2007 and has been in existence for over 19 years.
Eris Lifesciences is part of the BSE 500 index. Its director Amit Indubhushan Bakshi is #425 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24232GJ2007PLC049867. Its GSTIN is 24AABCE7067M1ZD (Gujarat). The company holds 29 GST registrations, of which 24 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 540596 and NSE: ERIS.
The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹13.86 Cr. It was formerly known as Eris Lifesciences Private Limited and Eris Lifescience Private Limited. It is led by directors including Amit Indubhushan Bakshi (Managing Director) and Inderjeet Singh Negi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 25 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹3,129.42 Cr, a growth of 8.1% compared to the previous year. For the same year it recorded a net profit of ₹632.03 Cr (net margin 20.2%) and EBITDA of ₹1,102.87 Cr (EBITDA margin 35.2%). The net worth stands at ₹3,902.67 Cr (up 36.7% YoY). Total assets are valued at ₹6,345.93 Cr (up 8.9% YoY).
The company has about 3,131 employees on its provident fund (EPFO) records. Its group structure includes 6 subsidiaries.
The company is associated with 1 brand: ERIs Life Sciences. As per MCA filings, the company has open charges of ₹1,524.82 Cr and satisfied charges of ₹1,252.5 Cr on record. Court records list 163 cases involving the company, including 91 filed by the company and 72 filed against it; 72 cases are pending. The company has 30 deals on record (21 market trades, 9 secondary share transfers); the latest was in October 2024. Its 10 peer companies in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Glaxosmithkline Pharmaceuticals Limited with revenue of ₹3,895.14 Cr. The company has 11 MSME Form 1 returns on record between 2019 and 2023, listing 571 overdue payments to 102 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website eris.co.in.
Company details
CIN L24232GJ2007PLC049867
Registration Number 049867
Incorporation Date 25 January 2007
ROC Ahmedabad
Listing Status Listed - Listed on NSE (ERIS); Listed on BSE (540596)
Company Status Active
Date of Last AGM 25 July 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
Name history
Eris Lifesciences has undergone 2 name changes throughout its history. The company was previously known as Eris Lifesciences Private Limited, and Eris Lifescience Private Limited. The current legal name is Eris Lifesciences Limited.
| Company Name | Status |
|---|---|
| Eris Lifesciences Limited | Current |
| Eris Lifesciences Private Limited | Previous |
| Eris Lifescience Private Limited | Previous |
CIN history
Eris Lifesciences has one previous CIN (Corporate Identification Number): U24232GJ2007PLC049867. The current CIN is L24232GJ2007PLC049867, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24232GJ2007PLC049867 | Current |
| U24232GJ2007PLC049867 | Previous |
Key People
Amit Indubhushan Bakshi Managing Director Inderjeet Singh Negi Whole-Time Director Kalpana Vasantrai Unadkat Director Recognitions & Rankings of Eris Lifesciences
India's Richest People 2026 edition · 1 director · Source: Hurun India
- #425 Amit Indubhushan Bakshi ₹8,800 Cr
Stock market indices
BSE 500
Contact details
Eris Lifesciences Limited's registered office is in Ahmedabad, Gujarat. Its website is eris.co.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressShivarth Ambit Plot No 142/2 Ramdas Road Off Sbr Near Swati Bungalows Bodakdev, Ahmedabad, Gujarat, India – 380054
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Eris Lifesciences Limited, buy the company report.
Comprehensive company report
Eris Lifesciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Eris Lifesciences operates one associated brand: ERIs Life Sciences. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical formulations for chronic diseases are manufactured and studied. | eris.co.in |
Business activity
The main business activity of Eris Lifesciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Eris Lifesciences Limited, buy the company report.
Financials of Eris Lifesciences Limited
FY 2025-26 filings availableEris Lifesciences Limited reported revenue of ₹3,129.42 Cr (up 8.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹3,129 Cr
+8.1% YoY
EBITDA
₹1,103 Cr
+8.4% YoY
Profit After Tax
₹632 Cr
+81.0% YoY
Net Worth
₹3,903 Cr
+36.7% YoY
Total Assets
₹6,346 Cr
+8.9% YoY
Total Debt
₹2,359 Cr
-4.8% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 3,129 | 2,894 | 2,056 | 1,733 | 1,347 | 1,212 | 1,074 |
| Revenue growth | +8.2% | +40.7% | +18.7% | +28.6% | +11.2% | +12.8% | - |
| EBITDA | 1,103 | 1,017 | 675 | 537 | 485 | 431 | 368 |
| EBITDA margin | +35.2% | +35.2% | +32.8% | +31.0% | +36.0% | +35.5% | +34.3% |
| Profit before tax | 639 | 489 | 431 | 405 | 442 | 394 | 331 |
| Net profit | 632 | 349 | 389 | 378 | 408 | 353 | 292 |
| Net profit margin | +20.2% | +12.1% | +18.9% | +21.8% | +30.3% | +29.1% | +27.2% |
| EPS (₹) | 44.73 | 25.83 | 28.83 | 28.10 | 29.88 | 26.16 | 21.84 |
| Balance sheet | |||||||
| Total assets | 6,346 | 5,830 | 6,064 | 3,160 | 2,030 | 1,621 | 1,337 |
| Net worth | 3,903 | 2,854 | 2,586 | 2,196 | 1,908 | 1,576 | 1,296 |
| Total debt | 2,359 | 2,478 | 2,781 | 877 | 84.41 | 6.78 | 0.00 |
| Cash & bank | 67.30 | 223 | 1,401 | 58.46 | 52.33 | 38.28 | 67.33 |
| Net working capital | 825 | 533 | 1,860 | 485 | 332 | 252 | 240 |
| Cash flow | |||||||
| Cash from operations | 538 | 1,065 | 486 | 292 | 378 | 375 | 271 |
| Cash from investing | (369) | (78.20) | (1,828) | (975) | (320) | (323) | 123 |
| Cash from financing | (314) | (881) | 1,380 | 688 | (44.70) | (82.40) | (335) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 892 | 873 | 757 | 807 | 792 | 773 | 705 | 727 |
| Revenue growth (YoY) | +12.6% | +13.0% | +7.3% | +11.0% | +6.9% | +7.4% | - | - |
| Other income | 3.20 | 2.39 | 2.23 | 0.14 | 3.09 | 3.58 | 8.01 | 4.22 |
| EBITDA | 273 | 296 | 272 | 264 | 288 | 277 | 252 | 250 |
| EBITDA margin | +30.6% | +34.0% | +36.2% | +33.0% | +36.5% | +35.9% | +35.9% | +34.7% |
| Depreciation | 73.42 | 72.07 | 69.57 | 70.34 | 69.08 | 70.51 | 77.25 | 81.00 |
| Interest | 46.42 | 46.65 | 45.62 | 48.82 | 49.55 | 48.68 | 54.28 | 57.17 |
| Profit before tax | 156 | 179 | 159 | 145 | 173 | 161 | 129 | 116 |
| Tax | (31.23) | 36.17 | (120) | 36.52 | 38.20 | 36.00 | 26.52 | 29.30 |
| Net profit | 187 | 143 | 279 | 109 | 134 | 125 | 102 | 87.06 |
| EPS (₹) | 13.25 | 10.26 | 20.57 | 7.31 | 8.81 | 8.64 | 6.89 | 6.15 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1,822 | 1,698 | 1,528 | 1,340 | 1,216 | 1,109 | 1,020 |
| Revenue growth | +7.3% | +11.1% | +14.0% | +10.3% | +9.6% | +8.7% | - |
| EBITDA | 598 | 487 | 454 | 505 | 484 | 417 | 356 |
| EBITDA margin | +32.8% | +28.7% | +29.7% | +37.7% | +39.8% | +37.7% | +34.9% |
| Profit before tax | 362 | 120 | 329 | 437 | 459 | 389 | 324 |
| Net profit | 254 | 74.56 | 297 | 393 | 419 | 348 | 287 |
| Net profit margin | +13.9% | +4.4% | +19.4% | +29.3% | +34.5% | +31.4% | +28.1% |
| EPS (₹) | 17.62 | 5.68 | 22.04 | 29.27 | 30.69 | 25.82 | 21.45 |
| Balance sheet | |||||||
| Total assets | 5,344 | 4,819 | 5,139 | 2,607 | 1,984 | 1,610 | 1,334 |
| Net worth | 3,195 | 2,515 | 2,524 | 2,222 | 1,919 | 1,575 | 1,300 |
| Total debt | 2,101 | 2,245 | 2,572 | 317 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 27.76 | 92.46 | 1,297 | 47.65 | 46.11 | 32.66 | 64.95 |
| Net working capital | 589 | 224 | 1,666 | 346 | 314 | 229 | 226 |
| Cash flow | |||||||
| Cash from operations | 564 | 702 | 336 | 322 | 369 | 395 | 265 |
| Cash from investing | (694) | (359) | (2,492) | (513) | (268) | (348) | 127 |
| Cash from financing | 71.06 | (310) | 2,160 | 194 | (88.42) | (81.13) | (334) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 482 | 444 | 277 | 315 | 650 | 579 | 405 | 400 |
| Revenue growth (YoY) | -25.9% | -23.3% | -31.5% | -21.1% | +49.0% | +26.7% | - | - |
| Other income | 19.24 | 26.38 | 26.97 | 25.07 | 23.59 | 22.68 | 16.75 | 7.79 |
| Total expenses | 335 | 324 | 256 | 253 | 354 | 362 | 284 | 300 |
| EBITDA | 147 | 120 | 21.78 | 62.68 | 297 | 216 | 121 | 99.57 |
| EBITDA margin | +31.2% | +27.6% | +8.1% | +20.4% | +46.6% | +38.1% | +30.6% | +25.5% |
| Depreciation | 40.88 | 39.98 | 38.82 | 38.66 | 39.30 | 37.60 | 43.38 | 46.68 |
| Interest | 42.06 | 42.16 | 42.70 | 45.20 | 46.50 | 45.14 | 53.16 | 54.65 |
| Profit before tax | 83.51 | 64.14 | (32.77) | 3.89 | 235 | 156 | 41.18 | 6.03 |
| Tax | (45.64) | 15.84 | (24.17) | 0.80 | 85.10 | 56.27 | 10.71 | 4.25 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 892 | 873 | 757 | 807 | 792 | 773 | 705 | 727 |
| Revenue growth (YoY) | +12.6% | +13.0% | +7.3% | +11.0% | +6.9% | +7.4% | - | - |
| Other income | 3.20 | 2.39 | 2.23 | 0.14 | 3.09 | 3.58 | 8.01 | 4.22 |
| EBITDA | 273 | 296 | 272 | 264 | 288 | 277 | 252 | 250 |
| EBITDA margin | +30.6% | +34.0% | +36.2% | +33.0% | +36.5% | +35.9% | +35.9% | +34.7% |
| Depreciation | 73.42 | 72.07 | 69.57 | 70.34 | 69.08 | 70.51 | 77.25 | 81.00 |
| Interest | 46.42 | 46.65 | 45.62 | 48.82 | 49.55 | 48.68 | 54.28 | 57.17 |
| Profit before tax | 156 | 179 | 159 | 145 | 173 | 161 | 129 | 116 |
| Tax | (31.23) | 36.17 | (120) | 36.52 | 38.20 | 36.00 | 26.52 | 29.30 |
| Net profit | 187 | 143 | 279 | 109 | 134 | 125 | 102 | 87.06 |
| EPS (₹) | 13.25 | 10.26 | 20.57 | 7.31 | 8.81 | 8.64 | 6.89 | 6.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 3,129 | 2,894 | 2,056 | 1,733 | 1,347 | 1,212 | 1,074 |
| Revenue growth | +8.2% | +40.7% | +18.7% | +28.6% | +11.2% | +12.8% | - |
| Other income | 7.84 | 18.42 | 23.82 | 11.15 | 26.09 | 8.71 | 15.40 |
| Total expenses | 2,027 | 1,876 | 1,381 | 1,196 | 862 | 781 | 706 |
| Employee cost | 557 | 505 | 404 | 346 | 250 | 229 | 206 |
| EBITDA | 1,103 | 1,017 | 675 | 537 | 485 | 431 | 368 |
| EBITDA margin | +35.2% | +35.2% | +32.8% | +31.0% | +36.0% | +35.5% | +34.3% |
| Depreciation | 280 | 315 | 183 | 117 | 64.71 | 42.99 | 50.26 |
| Interest | 193 | 231 | 84.80 | 26.17 | 4.22 | 1.98 | 2.30 |
| Profit before tax | 639 | 489 | 431 | 405 | 442 | 394 | 331 |
| Tax | (8.97) | 114 | 34.22 | 30.48 | 36.40 | 39.36 | 34.85 |
| Net profit | 632 | 349 | 389 | 378 | 408 | 353 | 292 |
| Net profit margin | +20.2% | +12.1% | +18.9% | +21.8% | +30.3% | +29.1% | +27.2% |
| EPS (₹) | 44.73 | 25.83 | 28.83 | 28.10 | 29.88 | 26.16 | 21.84 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 13.85 | 13.62 | 13.60 | 13.60 | 13.59 | 13.58 | 13.58 |
| Reserves & surplus | 3,889 | 2,841 | 2,573 | 2,182 | 1,894 | 1,563 | 1,283 |
| Shareholders' funds (net worth) | 3,903 | 2,854 | 2,586 | 2,196 | 1,908 | 1,576 | 1,296 |
| Minority interest | (7.01) | 417 | 636 | 24.69 | (0.11) | 0.00 | 0.00 |
| Secured loans | 2,309 | 2,421 | 1,753 | 830 | 45.00 | 0.00 | 0.00 |
| Unsecured loans | 49.14 | 56.49 | 1,028 | 46.71 | 39.41 | 6.78 | 0.00 |
| Total debt | 2,359 | 2,478 | 2,781 | 877 | 84.41 | 6.78 | 0.00 |
| Total liabilities | 6,346 | 5,830 | 6,064 | 3,160 | 2,030 | 1,621 | 1,337 |
| Assets | |||||||
| Gross block | 6,162 | 6,061 | 4,773 | 2,843 | 1,092 | 1,006 | 984 |
| Net block | 5,188 | 5,306 | 4,319 | 2,568 | 918 | 854 | 875 |
| Capital work in progress | 171 | 67.01 | 19.67 | 21.72 | 26.99 | 1.56 | 4.37 |
| Investments | 61.56 | 67.00 | 15.55 | 36.70 | 520 | 294 | 77.99 |
| Inventories | 437 | 335 | 189 | 131 | 118 | 94.47 | 69.48 |
| Sundry debtors | 680 | 459 | 422 | 293 | 161 | 140 | 157 |
| Cash & bank balances | 67.30 | 223 | 1,401 | 58.46 | 52.33 | 38.28 | 67.33 |
| Loans & advances | 355 | 205 | 290 | 252 | 197 | 143 | 111 |
| Total current assets | 1,540 | 1,221 | 2,302 | 735 | 528 | 417 | 405 |
| Total current liabilities | 714 | 688 | 442 | 250 | 196 | 165 | 165 |
| Net working capital | 825 | 533 | 1,860 | 485 | 332 | 252 | 240 |
| Total assets | 6,346 | 5,830 | 6,064 | 3,160 | 2,030 | 1,621 | 1,337 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 200 | 94.25 | 56.02 | 50.87 | 36.92 | 67.31 | 7.50 |
| Net cash from operating activities | 538 | 1,065 | 486 | 292 | 378 | 375 | 271 |
| Net cash from investing activities | (369) | (78.20) | (1,828) | (975) | (320) | (323) | 123 |
| Net cash from financing activities | (314) | (881) | 1,380 | 688 | (44.70) | (82.40) | (335) |
| Net change in cash | (145) | 105 | 38.13 | 5.15 | 13.96 | (30.39) | 59.81 |
| Closing cash | 67.30 | 223 | 1,401 | 58.46 | 52.33 | 38.28 | 67.33 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +8.2% | +40.7% | +18.7% | +28.6% | +11.2% | +12.8% | - |
| EBITDA growth | +8.4% | +50.7% | +25.7% | +10.7% | +12.6% | +16.9% | - |
| PBT growth | +30.6% | +13.3% | +6.6% | -8.5% | +12.1% | +19.1% | +4.4% |
| Net income growth | +81.0% | -10.3% | +3.0% | -7.3% | +15.6% | +20.8% | - |
| Revenue CAGR (3Y) | +21.8% | +29.0% | +19.3% | +17.3% | +11.1% | +12.3% | +12.7% |
| EBITDA CAGR (3Y) | +27.1% | +28.0% | +16.1% | +13.4% | +12.0% | +10.2% | +11.0% |
| Profitability & leverage | |||||||
| Net income margin | +20.7% | +13.0% | +19.3% | +21.6% | +30.1% | +29.3% | +27.6% |
| Return on capital employed | +14.1% | +13.3% | +12.1% | +16.7% | +24.5% | +26.8% | +24.8% |
| Return on net worth | +19.2% | +13.8% | +16.6% | +18.2% | +23.3% | +24.7% | +24.2% |
| Debt / equity | 0.72 | 0.97 | 0.76 | 0.23 | 0.03 | 0.00 | 0.07 |
| Long-term debt / equity | 0.57 | 0.50 | 0.29 | 0.19 | 0.02 | 0.00 | 0.00 |
| Interest cover | 23.40 | 32.96 | 17.22 | 6.24 | 1.00 | 0.51 | 0.72 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.51 | 0.53 | 0.54 | 0.88 | 1.28 | 1.22 | 1.18 |
| Inventory turnover | 8.11 | 11.05 | 12.83 | 13.90 | 12.69 | 14.78 | 14.12 |
| Debtors turnover | 5.50 | 6.57 | 5.75 | 7.64 | 8.94 | 8.15 | 8.92 |
| EPS (₹) | 44.73 | 25.83 | 28.83 | 28.10 | 29.88 | 26.16 | 21.84 |
| Dividend per share (₹) | 7.21 | 7.35 | 0.00 | 7.35 | 6.01 | 5.50 | 2.87 |
| Book value per share (₹) | 281.78 | 209.57 | 190.16 | 161.48 | 140.36 | 116.10 | 95.47 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 482 | 444 | 277 | 315 | 650 | 579 | 405 | 400 |
| Revenue growth (YoY) | -25.9% | -23.3% | -31.5% | -21.1% | +49.0% | +26.7% | - | - |
| Other income | 19.24 | 26.38 | 26.97 | 25.07 | 23.59 | 22.68 | 16.75 | 7.79 |
| Total expenses | 335 | 324 | 256 | 253 | 354 | 362 | 284 | 300 |
| EBITDA | 147 | 120 | 21.78 | 62.68 | 297 | 216 | 121 | 99.57 |
| EBITDA margin | +31.2% | +27.6% | +8.1% | +20.4% | +46.6% | +38.1% | +30.6% | +25.5% |
| Depreciation | 40.88 | 39.98 | 38.82 | 38.66 | 39.30 | 37.60 | 43.38 | 46.68 |
| Interest | 42.06 | 42.16 | 42.70 | 45.20 | 46.50 | 45.14 | 53.16 | 54.65 |
| Profit before tax | 83.51 | 64.14 | (32.77) | 3.89 | 235 | 156 | 41.18 | 6.03 |
| Tax | (45.64) | 15.84 | (24.17) | 0.80 | 85.10 | 56.27 | 10.71 | 4.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,822 | 1,698 | 1,528 | 1,340 | 1,216 | 1,109 | 1,020 |
| Revenue growth | +7.3% | +11.1% | +14.0% | +10.3% | +9.6% | +8.7% | - |
| Other income | 98.31 | 35.51 | 34.83 | 17.26 | 28.99 | 10.00 | 14.73 |
| Total expenses | 1,224 | 1,211 | 1,074 | 835 | 732 | 691 | 665 |
| Employee cost | 341 | 362 | 332 | 253 | 220 | 207 | 192 |
| EBITDA | 598 | 487 | 454 | 505 | 484 | 417 | 356 |
| EBITDA margin | +32.8% | +28.7% | +29.7% | +37.7% | +39.8% | +37.7% | +34.9% |
| Depreciation | 154 | 182 | 102 | 64.66 | 51.46 | 37.64 | 44.88 |
| Interest | 180 | 220 | 57.42 | 20.81 | 3.05 | 0.94 | 1.97 |
| Profit before tax | 362 | 120 | 329 | 437 | 459 | 389 | 324 |
| Tax | 118 | 42.66 | 29.12 | 38.91 | 41.34 | 38.28 | 32.32 |
| Net profit | 254 | 74.56 | 297 | 393 | 419 | 348 | 287 |
| Net profit margin | +13.9% | +4.4% | +19.4% | +29.3% | +34.5% | +31.4% | +28.1% |
| EPS (₹) | 17.62 | 5.68 | 22.04 | 29.27 | 30.69 | 25.82 | 21.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 13.85 | 13.62 | 13.60 | 13.60 | 13.59 | 13.58 | 13.58 |
| Reserves & surplus | 3,182 | 2,501 | 2,510 | 2,208 | 1,905 | 1,562 | 1,286 |
| Shareholders' funds (net worth) | 3,195 | 2,515 | 2,524 | 2,222 | 1,919 | 1,575 | 1,300 |
| Secured loans | 1,910 | 2,070 | 2,433 | 317 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 191 | 174 | 139 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | 2,101 | 2,245 | 2,572 | 317 | 0.00 | 0.00 | 0.00 |
| Total liabilities | - | - | 5,139 | 2,607 | 1,984 | 1,610 | 1,334 |
| Assets | |||||||
| Gross block | 2,913 | 2,875 | 1,811 | 1,095 | 778 | 717 | 696 |
| Net block | 2,353 | 2,412 | 1,516 | 898 | 642 | 584 | 601 |
| Capital work in progress | 0.00 | 0.27 | 0.61 | 0.34 | 2.98 | 1.56 | 4.37 |
| Investments | 1,414 | 991 | 1,619 | 997 | 778 | 531 | 320 |
| Inventories | 121 | 191 | 91.63 | 63.70 | 84.79 | 64.85 | 65.46 |
| Sundry debtors | 307 | 236 | 240 | 229 | 138 | 114 | 141 |
| Cash & bank balances | 27.76 | 92.46 | 1,297 | 47.65 | 46.11 | 32.66 | 64.95 |
| Loans & advances | 567 | 108 | 248 | 182 | 212 | 162 | 104 |
| Total current assets | 1,023 | 628 | 1,877 | 522 | 480 | 373 | 375 |
| Total current liabilities | 434 | 404 | 211 | 176 | 166 | 144 | 149 |
| Net working capital | 589 | 224 | 1,666 | 346 | 314 | 229 | 226 |
| Total assets | 5,344 | 4,819 | 5,139 | 2,607 | 1,984 | 1,610 | 1,334 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 84.34 | 51.93 | 47.48 | 44.70 | 31.35 | 64.93 | 6.46 |
| Net cash from operating activities | 564 | 702 | 336 | 322 | 369 | 395 | 265 |
| Net cash from investing activities | (694) | (359) | (2,492) | (513) | (268) | (348) | 127 |
| Net cash from financing activities | 71.06 | (310) | 2,160 | 194 | (88.42) | (81.13) | (334) |
| Net change in cash | (59.16) | 32.41 | 4.45 | 2.78 | 13.36 | (33.58) | 58.47 |
| Closing cash | 27.76 | 92.46 | 1,297 | 47.65 | 46.11 | 32.66 | 64.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +7.3% | +11.1% | +14.0% | +10.3% | +9.6% | +8.7% | - |
| EBITDA growth | +22.8% | +7.2% | -10.2% | +4.4% | +16.0% | +17.4% | - |
| PBT growth | +201.6% | -63.5% | -24.7% | -4.7% | +17.9% | +20.2% | +3.8% |
| Net income growth | +240.0% | -74.9% | -24.4% | -6.2% | +20.3% | +21.4% | - |
| Revenue CAGR (3Y) | +10.8% | +11.8% | +11.3% | +9.5% | +10.7% | +13.4% | +12.7% |
| EBITDA CAGR (3Y) | +5.8% | +0.2% | +2.8% | +12.4% | +13.2% | +9.7% | +9.5% |
| Profitability & leverage | |||||||
| Net income margin | +13.4% | +4.6% | +19.6% | +29.7% | +34.3% | +31.6% | +28.6% |
| Return on capital employed | +10.7% | +6.8% | +10.0% | +19.9% | +25.7% | +26.5% | +24.2% |
| Return on net worth | +8.6% | +3.1% | +12.6% | +19.2% | +23.9% | +24.4% | +23.7% |
| Debt / equity | 0.76 | 0.96 | 0.61 | 0.08 | 0.00 | 0.00 | 0.07 |
| Long-term debt / equity | 0.43 | 0.43 | 0.15 | 0.05 | 0.00 | 0.00 | 0.00 |
| Interest cover | 40.50 | 72.26 | 16.34 | 4.72 | 0.71 | 0.25 | 0.63 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.63 | 0.73 | 1.05 | 1.43 | 1.63 | 1.57 | 1.64 |
| Inventory turnover | 11.66 | 12.05 | 19.68 | 18.05 | 16.25 | 17.02 | 14.56 |
| Debtors turnover | 6.71 | 7.16 | 6.51 | 7.31 | 9.67 | 8.71 | 9.42 |
| EPS (₹) | 17.62 | 5.68 | 22.04 | 29.27 | 30.69 | 25.82 | 21.45 |
| Dividend per share (₹) | 7.21 | 7.35 | 0.00 | 7.35 | 6.01 | 5.50 | 2.87 |
| Book value per share (₹) | 230.72 | 184.65 | 185.59 | 163.39 | 141.11 | 116.03 | 95.72 |
To see the full year-wise statements and ratios of Eris Lifesciences Limited, buy the company report.
Board of directors of Eris Lifesciences Limited
Eris Lifesciences has 7 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Kalpana Vasantrai Unadkat | Director | 05 Jan 2021 | 5 Years 9 Months | Current |
| Vasudevan Sujesh | Director | 25 Jul 2022 | 4 Years 3 Months | Current |
| Amit Indubhushan Bakshi | Managing Director | 27 Jan 2007 | 19 Years 9 Months | Current |
| Inderjeet Singh Negi Also directs: Eris Healthcare Private Limited, Eris Therapeutics Limited, Eris Bionxt Private Limited and 3 more | Whole-Time Director | 25 Jan 2007 | 19 Years 9 Months | Current |
| Prashant Gupta | Director | 30 Apr 2018 | 8 Years 5 Months | Current |
| Kaushal Kamlesh Shah Also directs: Eris Healthcare Private Limited, Eris Therapeutics Limited, Aprica Healthcare Limited and 5 more | Director | 04 Aug 2020 | 6 Years 2 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Eris Lifesciences Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Limited | ₹3,895.14 Cr (FY 2025) | 9.0% | Mumbai, Maharashtra, India | |||
| Cadila Pharmaceuticals Limited | ₹3,869.17 Cr (FY 2025) | 4.0% | Ahmedabad, Gujarat, India | |||
| Acg Associated Capsules Private Limited | ₹3,600.7 Cr (FY 2025) | 10.0% | Mumbai, Maharashtra, India | |||
| Eris Lifesciences Limitedthis company | ₹3,129.42 Cr (FY 2026) | ₹632.03 Cr | 20.2% | 8.1% | 3,131 | Ahmedabad, Gujarat, India |
| Shreya Life Sciences Private Limited | ₹2,946.23 Cr (FY 2025) | 284.0% | Mumbai, Maharashtra, India | |||
| Amneal Pharmaceuticals Private Limited | ₹2,944.87 Cr (FY 2025) | 6.0% | Ahmedabad, Gujarat, India | |||
| Sandoz Private Limited | ₹2,778.2 Cr (FY 2025) | -2.0% | Navi Mumbai, Maharashtra, India | |||
| Biological E. Limited | ₹2,708 Cr (FY 2024) | -30.0% | Telangana, India | |||
| Pfizer Limited | ₹2,453.6 Cr (FY 2025) | 3.0% | Mumbai, Maharashtra, India | |||
| Marksans Pharma Limited | ₹2,227.83 Cr (FY 2024) | 17.0% | Mumbai, Maharashtra, India | |||
| Merck Life Science Private Limited | ₹2,200.06 Cr (FY 2025) | 7.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Eris Lifesciences Limited, buy the company report.
Auditor
Eris Lifesciences Limited is audited by Deloitte Haskins & Sells LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Deloitte Haskins & Sells LLP | FY 2023 | 117366W/W-100018 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 54.10%, foreign institutional investors hold 5.80%, domestic institutional investors hold 20.70% and retail and other public shareholders hold 19.40%.
Sep 2026
QUARTER
54.10% Promoters
20.70% DII (Domestic Institutional)
5.80% FII (Foreign Institutional)
19.40% Retail & Others
Promoter holding - history
Now 54.10% · Sep 2026High 54.80% · Dec 2025Low 53.90% · Jun 2026
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 54.10% | 53.90% | 54.80% | 54.80% |
| Public | 45.90% | 46.10% | 45.20% | 45.20% |
Charges & borrowings
Open charges
₹1,524.82 Cr
Satisfied charges
₹1,252.5 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 Apr 2025 | 101091534 | Hdfc Bank Limited | ₹150 Cr | Open | |
| 27 Dec 2023 | 100838342 | Hdfc Bank Limited | ₹212 Cr | Open | |
| 21 Dec 2023 | 100855337 | Citi Bank N.A. | ₹280 Cr | Open | |
| 21 Aug 2023 | 100795633 | Citi Bank N.A. | ₹120.82 Cr | Open | |
| 26 Jul 2023 | 100764843 | Axis Bank Limited | ₹337 Cr | Open |
To see the full charge records of Eris Lifesciences Limited, buy the company report.
Total charge records: 12 View all charges
Deals & funding
Eris Lifesciences Limited has 30 deals on record (21 market trades, 9 secondary share transfers); the latest was in October 2024.
Total deals
30
Market trades
21
Secondary share transfers
9
Deals on record (5 of 30)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Market trade | ₹280.7 Cr | Buyer: Motilal Oswal Financial Services Limited Seller: an individual |
| Jul 2023 | Market trade | ₹173.05 Cr | Buyer: Plutus Wealth Management LLP Seller: an individual |
| Apr 2022 | Market trade | ₹373.49 Cr | Buyer: Emerald Investments Private Limited Seller: an individual |
| Mar 2020 | Market trade | ₹129.18 Cr | Buyer: Emerald Investments Private Limited Seller: an individual |
| Feb 2020 | Market trade | ₹40.39 Cr | Buyer: Emerald Investments Private Limited Seller: Goldman Sachs Trust Goldman Sacs Brics Fund |
To see the full deal history of Eris Lifesciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Eris Lifesciences Limited has 163 court cases on record: 91 filed by Eris Lifesciences, 72 filed against it. 72 cases are pending and 91 are disposed.
Total cases
163
Filed by the company
91
Filed against the company
72
Pending
72
Disposed
91
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 93 | 47 | 47 |
| District courts | 59 | 16 | 19 |
| Supreme Court | 7 | 5 | 2 |
| NCLAT | 4 | 4 | 4 |
Cases on record (5 of 163)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Supreme Court | Court case (4704-Transfer Petitions : Criminal Transfer Petition under Section 406 Code of Criminal Procedure, 1973/Section 446 of the Bharatiya Nagarik Suraksha Sanhita, 2023) | Filed against the company by Krishna Pharmaceuticals Through Prop. and 1 other | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Torrent Pharmaceuticals Limited and 1 other | Pending |
| High Court of Delhi | Commercial suit | Filed by the company against Aaeris Lifecare Pvt Ltd & Ors. | Pending |
| High Court, GUJARAT | Special civil application | Filed by the company against Plexus Professionals Network Private Limited and 2 others | Pending |
| District court, BENGALURU, Karnataka | Civil suit | Filed by the company against Cytosorbents India Pvt Ltd | Pending |
To see the full case history of Eris Lifesciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Eris Lifesciences Limited has 11 MSME Form 1 returns on record between 2019 and 2023, listing 571 overdue payments to 102 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 102)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Footright Healthcare Private Limited | |||
| Nex Logistics Private Limited |
To see the full MSME payment records of Eris Lifesciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Eris Lifesciences has 6 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
6
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Eris Healthcare Private Limited | U24211GJ2013PTC113419 | |
| Eris Therapeutics Limited | U24230GJ2021PLC123519 | |
| Aprica Healthcare Limited | U24232GJ2011PLC112374 | |
| Eris Pharmaceuticals Private Limited | U33100UP2020PTC128964 | |
| Eris M. J. Biopharm Private Limited | U51397GJ2002PTC112851 | |
| Eris Oaknet Healthcare Private Limited | U74999MH2011PTC296817 |
To see the full group structure of Eris Lifesciences Limited, buy the company report.
Employees & EPFO
Eris Lifesciences Limited has a workforce of 3,131 employees on its EPFO records as of Mar 06, 2025, across 2 active EPFO establishments.
Employee count
3,131
Active EPFO establishments
2
Employee growth
-5.26%
GST
Eris Lifesciences has 29 GST registrations: 24 active and 5 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
29
Active
24
Cancelled / inactive
5
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AABCE7067M1ZD | Gujarat | Active | 01 Jul 2017 |
| 24AABCE7067M2ZC | Gujarat | Active | 10 Jul 2017 |
| 03AABCE7067M1ZH | Punjab | Active | 01 Jul 2017 |
| 05AABCE7067M1ZD | Uttarakhand | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Eris Lifesciences Limited, buy the company report.
Recent activity
Eris Lifesciences Limited has 29 board changes on record since 2007: 19 appointments and 10 cessations. The latest: Vineet Varma was appointed as Director on 14 Mar 2026.
Charges
A charge with Hdfc Bank Limited of Rs. 300.00 Cr registered on 02 Jun 2022 with Charge ID 100581972 was modified on 14 Jul 2026.
Filing
Eris Lifesciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Appointed
Vineet Varma was appointed as Director.
AGM
Eris Lifesciences Limited last Annual general meeting of members was held on 25 Jul 2025 as per latest MCA records.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 150.00 Cr with Charge ID 101091534 was registered on 04 Apr 2025.
Charges
A charge registered on 13 Feb 2024 via Charge ID 100890095 with Others was fully satisfied on 21 Feb 2025.
Charges
A charge with Others amounted to Rs. 437.50 Cr with Charge ID 100890095 was registered on 13 Feb 2024.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 212.00 Cr with Charge ID 100838342 was registered on 27 Dec 2023.
Charges
A charge with Citi Bank N.A. amounted to Rs. 280.00 Cr with Charge ID 100855337 was registered on 21 Dec 2023.
Charges
A charge with Citi Bank N.A. amounted to Rs. 120.82 Cr with Charge ID 100795633 was registered on 21 Aug 2023.
Charges
A charge with Axis Bank Limited amounted to Rs. 337.00 Cr with Charge ID 100764843 was registered on 26 Jul 2023.
Charges
A charge with Citi Bank N.A. amounted to Rs. 125.00 Cr with Charge ID 100733714 was registered on 31 May 2023.
39 earlier events are in the company report.
News
Eris Lifesciences: Macquarie on Eris Lifesciences Maintains Outperform, Target Price ₹1,575; Q2FY27 revenue and EBITDA were 2% above estimates, while adjusted PAT was broadly in line. Domestic revenue grew 14.1% YoY, or 16.5% excluding the portfolio licensed to Zorvia Healthcare, led by OAD, cardiac, VMN and diabetes growth; international revenue was flat YoY but rose around 15% QoQ.
ERIS: Q2 CONS NET PROFIT 1.84B RUPEES VS 1.2B (YOY); EST 1.45B
ERIS: Q2 EBITDA 3.1B RUPEES VS 2.9B (YOY); Q2 EBITDA MARGIN 34.67% VS 36.37% (YOY)
ERIS: Q2 REVENUE 8.9B RUPEES VS 7.9B (YOY)
Frequently asked questions
Eris Lifesciences is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 January 2007 (19+ years old) and is registered under CIN L24232GJ2007PLC049867. Listed on BSE: 540596 and NSE: ERIS.
Eris Lifesciences reported revenue of ₹3,129.42 Cr for FY 2025-26 (up 8.1% YoY) based on consolidated financials.
Eris Lifesciences has 7 current directors:
- Amit Indubhushan Bakshi - Managing Director
- Inderjeet Singh Negi - Whole-Time Director
- Kalpana Vasantrai Unadkat - Director
- Vasudevan Sujesh - Director
- Prashant Gupta - Director
- Kaushal Kamlesh Shah - Director
- Vineet Varma - Director
The latest financial statements of Eris Lifesciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Eris Lifesciences is 24AABCE7067M1ZD, registered in Gujarat. The company has 29 GST registrations in all, of which 24 are active and 5 are cancelled or inactive. Other active GSTINs include 24AABCE7067M2ZC (Gujarat), 03AABCE7067M1ZH (Punjab), 05AABCE7067M1ZD (Uttarakhand).
The CIN (Corporate Identification Number) of Eris Lifesciences is L24232GJ2007PLC049867. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Eris Lifesciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 540596) and NSE (symbol: ERIS).
Eris Lifesciences has 163 court cases on record: 91 filed by the company and 72 filed against it. 72 are pending. Most are in the high courts.
Eris Lifesciences was incorporated on 25 January 2007, making it 19+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Eris Lifesciences has 30 deals on record (21 market trades, 9 secondary share transfers); the latest was in October 2024.
The peers of Eris Lifesciences by revenue are Glaxosmithkline Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Acg Associated Capsules Private Limited, Shreya Life Sciences Private Limited, Amneal Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Lifesciences), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Vineet Varma was appointed as Director on 14 Mar 2026. Vasudevan Sujesh was appointed as Director on 25 Jul 2022. Vijaya Sampath ceased to be Director on 19 Jul 2022. Eris Lifesciences has 29 board changes on record in total.